Latest Acelrx Pharmaceuticals (ACRX) Headlines
AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
PR Newswire - Fri Mar 07, 3:45PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference:
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why AcelRx Pharmaceuticals, Inc. Shares Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 04, 12:42PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of specialty drug company AcelRx...
GMO Inside Announces Campaign to Get GMOs Out of Starbucks' Dairy
PR Newswire - Tue Mar 04, 9:00AM CST
Green America's GMO Inside campaign today launched a major push to get Starbucks, America's largest coffee chain with more than 20,000 stores in 62 countries, to serve only organic milk sourced from cows not fed GMOs. In early January, GMO Inside made worldwide headlines when its social media campaign led General Mills to announce that it would drop genetically modified ingredients in basic Cheerios.
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 03, 3:05PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013.
AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
PR Newswire - Mon Feb 24, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 3, 2014 to discuss the financial results and provide a corporate update.
PAREXEL Simplifies Drug Development Journey From Science To New Treatments
PR Newswire - Wed Feb 12, 5:00AM CST
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 9:35AM CST
Mallinckrodt beats Q1 earnings estimates.
AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
PR Newswire - Wed Feb 05, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences. Details of the three events are as follows:
Cempra (CEMP) Falls: Stock Plunges 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:47AM CST
Cempra's shares fell nearly 11% yesterday, continuing the most recent downtrend for CEMP, as the stock is down almost 16% since Jan 10.
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:19AM CST
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout?
Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
This Guy Used Reddit to Build a Crowdsourced Stock Portfolio. The Results Were Actually Not Bad ...
Jay Jenkins, The Motley Fool - Motley Fool - Sun Dec 22, 9:36AM CST
Late last year, Reddit user PhantomPumpkin began building a simulated portfolio . Over a three-week period, he invested $10,000 in play money into any stock talked about positively on the subreddit r/investing. Is this a viable portfolio building...
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 19, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Strategic Acquisitions, Commercial Collaborations, and New Appointments - Research Report on Solta Medical, Opko Health, NuPathe, AcelRx Pharmaceuticals, and Momenta Pharmaceuticals
PR Newswire - Thu Dec 19, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Solta Medical, Inc. (NASDAQ: SLTM), Opko Health, Inc. (NYSE: OPK), NuPathe, Inc. (NASDAQ: PATH), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
PR Newswire - Thu Dec 19, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has entered into a new amended and restated credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) that extends AcelRx's current relationship with Hercules, which was established in June 2011. The new Hercules credit facility provides for up to $40 million of new loans.
EnerCare Inc. Announces Monthly Dividend
Marketwire Canada - Wed Dec 18, 6:22AM CST
EnerCare Inc. ("EnerCare") (TSX:ECI) today announced a cash dividend of $0.058 per common share for the month of December 2013. The dividend will be payable on January 31, 2014 to shareholders of record at the close of business on December 31, 2013. This dividend is designated as an "eligible dividend" for Canadian income tax purposes.
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Up 17.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 17, 6:51AM CST
AcelRx Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 18% on the day.
AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
PR Newswire - Fri Mar 07, 3:45PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference:
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why AcelRx Pharmaceuticals, Inc. Shares Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 04, 12:42PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of specialty drug company AcelRx...
GMO Inside Announces Campaign to Get GMOs Out of Starbucks' Dairy
PR Newswire - Tue Mar 04, 9:00AM CST
Green America's GMO Inside campaign today launched a major push to get Starbucks, America's largest coffee chain with more than 20,000 stores in 62 countries, to serve only organic milk sourced from cows not fed GMOs. In early January, GMO Inside made worldwide headlines when its social media campaign led General Mills to announce that it would drop genetically modified ingredients in basic Cheerios.
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 03, 3:05PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013.
AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
PR Newswire - Mon Feb 24, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 3, 2014 to discuss the financial results and provide a corporate update.
PAREXEL Simplifies Drug Development Journey From Science To New Treatments
PR Newswire - Wed Feb 12, 5:00AM CST
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.
Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 9:35AM CST
Mallinckrodt beats Q1 earnings estimates.
AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
PR Newswire - Wed Feb 05, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences. Details of the three events are as follows:
Cempra (CEMP) Falls: Stock Plunges 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:47AM CST
Cempra's shares fell nearly 11% yesterday, continuing the most recent downtrend for CEMP, as the stock is down almost 16% since Jan 10.
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:19AM CST
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout?
Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
This Guy Used Reddit to Build a Crowdsourced Stock Portfolio. The Results Were Actually Not Bad ...
Jay Jenkins, The Motley Fool - Motley Fool - Sun Dec 22, 9:36AM CST
Late last year, Reddit user PhantomPumpkin began building a simulated portfolio . Over a three-week period, he invested $10,000 in play money into any stock talked about positively on the subreddit r/investing. Is this a viable portfolio building...
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 19, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Strategic Acquisitions, Commercial Collaborations, and New Appointments - Research Report on Solta Medical, Opko Health, NuPathe, AcelRx Pharmaceuticals, and Momenta Pharmaceuticals
PR Newswire - Thu Dec 19, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Solta Medical, Inc. (NASDAQ: SLTM), Opko Health, Inc. (NYSE: OPK), NuPathe, Inc. (NASDAQ: PATH), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
PR Newswire - Thu Dec 19, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has entered into a new amended and restated credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) that extends AcelRx's current relationship with Hercules, which was established in June 2011. The new Hercules credit facility provides for up to $40 million of new loans.
EnerCare Inc. Announces Monthly Dividend
Marketwire Canada - Wed Dec 18, 6:22AM CST
EnerCare Inc. ("EnerCare") (TSX:ECI) today announced a cash dividend of $0.058 per common share for the month of December 2013. The dividend will be payable on January 31, 2014 to shareholders of record at the close of business on December 31, 2013. This dividend is designated as an "eligible dividend" for Canadian income tax purposes.
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Up 17.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 17, 6:51AM CST
AcelRx Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 18% on the day.
